DOCSLIB.ORG

Modulation of Α1β3γ2 GABAA Receptors Expressed in X

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Modulation of Α1β3γ2 GABAA Receptors Expressed in X Modulation of α1β3γ2 GABAA receptors expressed in X. laevis oocytes using a propofol photoswitch tethered to the transmembrane helix Cecilia M. Borghesea,b,1, Hua-Yu L. Wangc, Stanton F. McHardyc, Robert O. Messinga,b, James R. Trudelld,e,2, R. Adron Harrisa,b, and Edward J. Bertaccinid,f aWaggoner Center for Alcohol and Addiction Research, The University of Texas at Austin, Austin, TX 78712; bDepartment of Neuroscience, The University of Texas at Austin, Austin, TX 78712; cCenter for Innovative Drug Discovery, University of Texas at San Antonio, San Antonio, TX 78249; dDepartment of Anesthesia, Stanford University, Palo Alto, CA 94305; eBeckman Program for Molecular and Genetic Medicine, Stanford University, Palo Alto, CA 94305; and fDepartment of Anesthesia, Palo Alto VA Health Care System, Palo Alto Division, Palo Alto, CA 94304 Edited by Ehud Y. Isacoff, University of California, Berkeley, CA, and approved January 13, 2021 (received for review April 29, 2020) Tethered photoswitches are molecules with two photo-dependent The GABAA receptor is formed by five subunits (usually two isomeric forms, each with different actions on their biological tar- α, two β, and one γ or δ) arranged in pseudosymmetry around a gets. They include reactive chemical groups capable of covalently central channel, in the following order (counterclockwise, viewed binding to their target. Our aim was to develop a β-subunit-teth- from the extracellular side): γ-β-α-β-α (2). Each interface is ered propofol photoswitch (MAP20), as a tool to better study the named after the subunits that form it, with “+” and “−” designated α β γ mechanism of anesthesia through the GABAA 1 3 2 receptor. We following the counterclockwise order (a model of the α1β3γ2 used short spacers between the tether (methanethiosulfonate), GABAA receptor can be found in SI Appendix,Fig.S1). Each the photosensitive moiety (azobenzene), and the ligand (propo- subunit consists of an extracellular domain, attached to a sequence fol), to allow a precise tethering adjacent to the putative propofol of four transmembrane helices (TMs), with a large intracellular + − binding site at the β α interface of the receptor transmembrane loop inserted between TM3 and TM4. Multiple anesthetic drugs helices (TMs). First, we used molecular modeling to identify possi- that act through this receptor possess relatively low binding affin- ble tethering sites in β3TM3 and α1TM1, and then introduced cys- ities; therefore, precise identification and characterization of their PHARMACOLOGY β teines in the candidate positions. Two mutant subunits [ 3(M283C) binding sites require the use of techniques like mutagenesis, α and 1(V227C)] showed photomodulation of GABA responses af- substituted cysteine modification protection (SCAMP), and pho- ter incubation with MAP20 and illumination with lights at specific tolabeling with photoreactive anesthetic analogs (3). Structures of wavelengths. The α1β3(M283C)γ2 receptor showed the greatest the GABAA receptor with bound anesthetic drugs have recently photomodulation, which decreased as GABA concentration in- been made available (4), but one unexplored way of obtaining creased. The location of the mutations that produced photomodu- valuable, functional information would be by using appropriately lation confirmed that the propofol binding site is located in the − designed tethered photoswitches. In previous studies of GABA β+α interface close to the extracellular side of the transmembrane A receptors, the photoswitches used have included diffusible propofol helices. Tethering the photoswitch to cysteines introduced in the photoswitches (5, 6) and a tethered propofol photoswitch with a positions homologous to β3M283 in two other subunits (α1W288 and γ2L298) also produced photomodulation, which was not en- tirely reversible, probably reflecting the different nature of each Significance interface. The results are in agreement with a binding site in the β+α− interface for the anesthetic propofol. Mechanisms of anesthesia remain obscure. We developed a β-subunit-specific tethered photoswitch containing the widely optopharmcology | anesthetic | molecular modeling | azobenzene | used anesthetic, propofol, to study the anesthetic mechanisms methanethiosulfonate through γ-aminobutyric acid type A (GABAA) receptors critical for this drug’s effects. Photoswitches are molecules that shift hile photoswitches have been a popular topic in numerous between two isomeric forms after irradiation with light at a Wreviews (1), their application in research is still very rare. specific wavelength, which would produce different biological Photoswitches are freely diffusible molecules containing a pho- outcomes on their targets. Tethered photoswitches possess tosensitive moiety which can alternate between two isomeric reactive groups that can covalently bind to their target. We forms depending on light irradiation at specific wavelengths. identified several residues in the receptor transmembrane do- These isomeric forms of the photoswitch possess different af- mains that are suitable for tethering. Once bound and after photoirradiation, the propofol moiety of MAP20 swings into its finities or efficacies toward their biological target, such that their binding site, allowing for light-controlled potentiation of the pharmacological activity can be turned on or off depending on GABA receptor expressed in Xenopus laevis oocytes. the light wavelength used, thus providing temporal and spatial A control. When photoswitches covalently tether to a native or Author contributions: C.M.B., J.R.T., R.A.H., and E.J.B. designed research; C.M.B., engineered residue at the specific biological target, the resulting H.-Y.L.W., S.F.M., J.R.T., and E.J.B. performed research; H.-Y.L.W. and S.F.M. contributed conformation would determine the corresponding pharmaco- new reagents/analytic tools; C.M.B., H.-Y.L.W., S.F.M., R.O.M., J.R.T., R.A.H., and E.J.B. logical activity. One way the tethered photoswitch can be acti- analyzed data; and C.M.B., H.-Y.L.W., S.F.M., R.O.M., R.A.H., and E.J.B. wrote the paper. vated is by positioning the tether in such a way that the ligand The authors declare no competing interest. moiety can reach its binding site in only one of the photoswitch This article is a PNAS Direct Submission. conformations. Additional major advantages of the tethered Published under the PNAS license. photoswitches are high local concentration (the residue cannot 1To whom correspondence may be addressed. Email: [email protected]. diffuse away) and spatial restriction within the biological target. 2Deceased July 29, 2019. The ligand groups of photoswitches can possess diverse phar- This article contains supporting information online at https://www.pnas.org/lookup/suppl/ macological activities, acting as agonists, inverse agonists, or doi:10.1073/pnas.2008178118/-/DCSupplemental. antagonists at specific binding sites. Published February 15, 2021. PNAS 2021 Vol. 118 No. 8 e2008178118 https://doi.org/10.1073/pnas.2008178118 | 1of8 Downloaded by guest on September 30, 2021 very long spacer between the tethering cysteine (located in the this tethered photoswitch are connected by short spacers, decreas- extracellular domain) and the propofol moiety (6). Though all ing the range between tethering and target residues. We used β3 three positively modulated GABAA receptors, none could be used subunits in our study because the immobilizing and hypnotic effects to define the propofol binding site. of propofol are mostly mediated by β3-containing receptors (10). Multiple studies point to propofol binding cavities being lo- Results cated in the TM interfaces between GABAA receptor subunits. The observation that specific mutations in TM2 or TM3 of GABAA Before testing the photoswitch in relevant cysteine mutants, β subunits could dramatically decrease propofol potentiation of endogenous cysteines located in the TM and extracellular domains GABA responses, and even direct activation of the receptor (7–9) of the GABAA subunits were replaced by alanines, creating a led to the development of the β3(N265M) knockin mouse, which Cys-to-Ala background into which tethering cysteines could be showed either a greatly decreased or absent hypnotic effect of introduced without fear of endogenous cysteines interfering with propofol, depending on the test used (10). More recent studies have the interpretation of the photomodulation results. The function of focused on a more complete characterization of binding sites for the resulting Cys-to-Ala α1β3γ2GABAA receptor was compared propofol as well as other intravenous anesthetics. A photoreactive with the wild-type receptor, and no differences were observed, − propofol analog labeled three amino acids in the β+α interface except for a modest, albeit significant, increase in propofol po- − (β3M286, α1M236, and α1I239) and one in the α+β interface tentiation (SI Appendix, Fig. S2 and Table S1). (β3M227) in α1β3 receptors. Using etomidate and R-mTFD-MPAB We used molecular modeling to position propofol in the pu- β+α− [R-5-allyl-1-methyl-5-(m-trifluoromethyldiazirinylphenyl)barbituric tative binding site located in the interface in a GABAA acid] to inhibit photolabeling established that propofol also binds to receptor structure. This cavity is lined by several residues critical − the β+β interface, suggesting that propofol shows little selectivity for propofol action: βN265 and βM286, and αL232 and αM236. for either interface (11). Another study mutated photolabeled res- Then we added the
Load more

Recommended publications
  • Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: a Retrospective Study
    medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252883; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Title page Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study Running Title: Mild COVID-19 and the Buffet of Treatments: A case series Sayak Roy1, Shambo Samrat Samajdar2, Santanu K Tripathi3, Shatavisa Mukherjee4, Kingshuk Bhattacharjee5 1. Consultant Physician, Dept. of Internal Medicine, Medica Superspeciality Hospital, Kolkata; ORCID ID: https://orcid.org/0000-0002-6185-9375 2. Senior Resident, Dept of Clinical & Experimental Pharmacology, School of Tropical Medicine, Kolkata. 3. Dean (Academics) and Head, Dept of Pharmacology, Netaji Subhash Medical College & Hospital, Bihta, Patna 4. PhD Research Scholar, Dept of Clinical & Experimental Pharmacology, School of Tropical Medicine, Kolkata. ORCID ID: https://orcid.org/0000-0001-9524-1525 5. Independent Biostatistician, Kolkata Corresponding Author: Dr. Sayak Roy 609, G.T.Road, Battala, Serampore, Hooghly, WB, India; PIN – 712201 Email: [email protected] Words: 1906 Tables: 2 References: 20 Informed Consent and Institutional ethical clearance: Taken Conflicts of interest: None Funding: None Acknowledgement: None Data availability: Available on request with the corresponding author NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252883; this version posted March 12, 2021.
    [Show full text]
  • Exploring the Activity of an Inhibitory Neurosteroid at GABAA Receptors
    1 Exploring the activity of an inhibitory neurosteroid at GABAA receptors Sandra Seljeset A thesis submitted to University College London for the Degree of Doctor of Philosophy November 2016 Department of Neuroscience, Physiology and Pharmacology University College London Gower Street WC1E 6BT 2 Declaration I, Sandra Seljeset, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I can confirm that this has been indicated in the thesis. 3 Abstract The GABAA receptor is the main mediator of inhibitory neurotransmission in the central nervous system. Its activity is regulated by various endogenous molecules that act either by directly modulating the receptor or by affecting the presynaptic release of GABA. Neurosteroids are an important class of endogenous modulators, and can either potentiate or inhibit GABAA receptor function. Whereas the binding site and physiological roles of the potentiating neurosteroids are well characterised, less is known about the role of inhibitory neurosteroids in modulating GABAA receptors. Using hippocampal cultures and recombinant GABAA receptors expressed in HEK cells, the binding and functional profile of the inhibitory neurosteroid pregnenolone sulphate (PS) were studied using whole-cell patch-clamp recordings. In HEK cells, PS inhibited steady-state GABA currents more than peak currents. Receptor subtype selectivity was minimal, except that the ρ1 receptor was largely insensitive. PS showed state-dependence but little voltage-sensitivity and did not compete with the open-channel blocker picrotoxinin for binding, suggesting that the channel pore is an unlikely binding site. By using ρ1-α1/β2/γ2L receptor chimeras and point mutations, the binding site for PS was probed.
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • A Pilot Study of the Safety and Initial Efficacy of Ivermectin for The
    ALCOHOLISM:CLINICAL AND EXPERIMENTAL RESEARCH Vol. 40, No. 6 June 2016 A Pilot Study of the Safety and Initial Efficacy of Ivermectin for the Treatment of Alcohol Use Disorder Daniel J. O. Roche, Megan M. Yardley, Katy F. Lunny, Stan G. Louie, Daryl L. Davies, Karen Miotto, and Lara A. Ray Background: Ivermectin (IVM) is an antiparasitic agent that has been shown to reduce alcohol intake in mice, suggesting IVM as a potential treatment for alcohol use disorder (AUD). However, the safety profile of IVM administered in combination with an intoxicating dose of alcohol has not been characterized in humans. Methods: This pilot project sought to provide the first clinical evidence that IVM could be reposi- tioned as an AUD pharmacotherapy by examining (i) the safety of combining IVM (30 mg oral , once a day [QD]) with an intoxicating dose of intravenous alcohol (0.08 g/dl) and (ii) the effects of IVM on alcohol cue-induced craving and subjective response to alcohol. Eleven individuals with AUD partici- pated in a randomized, placebo-controlled, crossover study in which they received the study medica- tion, participated in a cue exposure paradigm followed by intravenous alcohol administration, and remained in an inpatient unit overnight for observation. Results: IVM treatment, versus placebo, did not increase the number or severity of adverse effects during alcohol administration or throughout the visit. However, IVM did not reduce cue-induced crav- ing nor did it significantly affect subjective response to alcohol. Conclusions: These results suggest that IVM (30 mg oral, QD) is safe in combination with an intoxi- cating dose of alcohol, but do not provide evidence that this dose of IVM is effective in reducing alcohol craving or its reinforcing effects.
    [Show full text]
  • Ivermectin and Human Immunity Protocol ID
    Cover Sheet Clinicaltrials.gov ID NCT03459794 Protocol Ivermectin and human immunity ID#STUDY00005069 Adrian Adrian PI: Primary Contact: Wolstenholme Wolstenholme Submission Initial Study Type: IRB Brooke Harwell Parent Protocol: Coordinator: Review Category: Approved 9/27/2017 Date: Expiration 7/11/2018 Date: Print: STUDY00005069 - Ivermectin and human immunity https://ovpr-click-prod.ovpr.uga.edu/uga-ovpr/ResourceAdministration/P... Date: Monday, November 26, 2018 12:06:50 PM View: SF: Basic Information UGA v2 Section 1 - Basic Information 1. * Title of Study: If the study is/will be funded, the IRB recommends The effects of ivermectin on the normal human matching the title in the funding proposal. immune system 2. * Short Title: This can match the long title or be shortened if your Ivermectin and human immunity project uses an acronym or nickname; however, all system generated lists, searches, and documents (including approval letters) will show the short title. 3. Only UGA faculty and selected staff members (senior Principal Investigator (faculty or senior staff) are eligible to serve as PI. See the policy for staff only - see help): more information: http://research.uga.edu/documents Adrian Wolstenholme /eligibility 4. * Does the Principal Investigator have a See the policy for more information: https://research.uga.edu/docs/policies financial interest related to this /compliance research? Yes No /hso/PP_Financial%20Conflicts%20of%20Interests.pdf 5. If you are not sure if your project needs IRB * Are you requesting determination if review, choose "Yes" in the first question. A form will your project meets the definition of open and provide prompts to guide you through an initial assessment to see if your project needs IRB Yes No human subjects research? review.
    [Show full text]
  • During Prepartum Period on Mastitis and Postpartum Reproductive Efciency Measurements in Egyptian Baladi Cows
    Impact of treatment with anti-parasitic (Ivermectin) during prepartum period on mastitis and postpartum reproductive eciency measurements in Egyptian Baladi cows Ahmed Ismail Damarany ( [email protected] ) Aswan University Faculty of Agriculture and Natural Resources https://orcid.org/0000-0002-0757-933X Research Article Keywords: Ivermectin, mastitis, postpartum reproductive eciency measurements, Baladi cows Posted Date: August 23rd, 2021 DOI: https://doi.org/10.21203/rs.3.rs-823328/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/19 Abstract The current investigation was designed to determine the effect of treatment with anti-parasites (Ivermectin) on mastitis and postpartum reproductive eciency measurements in Egyptian Baladi cows. Twenty-four of the cows included in this study were split into two groups. The rst group (n = 12 cows) was injected two months prepartum with two doses (15 days inter-treatment) of IVOMEC® Plus solution subcutaneously behind the shoulder, 1ml/50kg live body weight as prescribed by the manufacturer, whilst the other group (n = 12 cows) was used as a control group. The present results revealed that the incident rate of mastitis in treated cows’ group was signicantly (P < 0.05) lower (16.7%) than control cows’ group (41.7%). The conception rate in treated cows’ group was signicantly (P < 0.05) higher (66.7%) compared with (33.3%) in control group. The time from calving to conception in treated cows was signicantly (P < 0.05) lower 86.5 ± 11.4 days compared to 123.3 ± 13.2 days in the control group.
    [Show full text]
  • Crystal Polymorphism and Pseudopolymorphism of Ivermectin
    Crystal polymorphism and pseudopolymorphism of ivermectin Michiel Lucas Josias Grobler B.Pharm. Dissertation submitted in partial fulfilment of the requirements for the degree Magister Scientiae in the Department of Pharmaceutics at the Potchefstroomse Universiteit vir Christelike Hoer Onderwys. Supervisor: Prof. M.M. de Villiers. Co-superviso·rs: Dr. W. Liebenberg. Mr. A.F. Marais. POTCHEFSTROOM 2000 TABLE OF CONTENTS TABLE OF CONTENTS ABSTRACT vii UITTREKSEL ix AIM AND OBJECTIVES xi CHAPTER 1: Veterinary formulation: the influence of animal and environmental factors and the solid state properties of drugs 1.1 Introduction 1 1.2 Veterinary dosage forms 2 1.3 Animal and environmental factors influencing veterinary formulation 3 design 1.3.1 Geographical location 3 1.3.2 Dietary habit 4 1.3.3 Gastrointestinal tract 4 1.3.4 Metabolism 5 1.3.5 Renal excretion 6 1.3.6 Biliary excretion 6 1.3. 7 Skin type 7 1 .3.8 Endocrinology 7 1.3.9 Animal behaviour 7 1.3.10 Drug distribution 7 1.3.11 Age 8 1.3.12 Disease states 9 1.3.13 Residues 9 1.3.14 Single or herd dosing 9 1.3.15 Wild or tame 10 1.3.16 Stability 11 1.4 Solid state properties of drugs that influence veterinary formulation 11 design 1.4.1 Effect of particle size on veterinary drug formulations 12 1.4.1.1 Effect of particle size on dissolution and solubility 12 1.4.1.2 Effect of particle size on suspension stability 13 1.4.1.3 Effect of particle size reduction on drug stability 14 1.4.1.4 Effect of particle size on administration of drugs in feed 14 1.4.2 The effect of crystal forms
    [Show full text]
  • Interactions with Protease Inhibitors Charts Revised February 2018
    www.hiv-druginteractions.org Interactions with Protease Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ATV Cobi DRV FPV IDV LPV RTV SQV TPV ATV Cobi DRV FPV IDV LPV RTV SQV TPV Anaesthetics & Muscle Relaxants Antibacterials (continued) Alcuronium Ertapenem Bupivacaine Erythromycin Cisatracurium Ethambutol Desflurane Ethionamide Dexmedetomidine Flucloxacillin Enflurane Gentamicin Ephedrine Imipenem/Cilastatin Halothane Isoniazid Isoflurane Kanamycin Ketamine Levofloxacin Linezolid Nitrous oxide Meropenem Propofol Metronidazole Rocuronium Moxifloxacin Sevoflurane Nitrofurantoin Sufentanil Ofloxacin Suxamethonium (succinylcholine) Para-aminosalicylic acid Tetracaine Penicillins Thiopental for distribution. for Pyrazinamide Tizanidine Rifabutin Vecuronium Rifampicin Analgesics Rifapentine Alfentanil Rifaximin Aspirin Spectinomycin Buprenorphine Streptomycin Celecoxib Sulfadiazine Codeine Telithromycin Tetracyclines
    [Show full text]
  • Calcium-Engaged Mechanisms of Nongenomic Action of Neurosteroids
    Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Rebas, Elzbieta, Tomasz Radzik, Tomasz Boczek, and Ludmila Zylinska. 2017. “Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids.” Current Neuropharmacology 15 (8): 1174-1191. doi:10.2174/1570159X15666170329091935. http:// dx.doi.org/10.2174/1570159X15666170329091935. Published Version doi:10.2174/1570159X15666170329091935 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:37160234 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA 1174 Send Orders for Reprints to [email protected] Current Neuropharmacology, 2017, 15, 1174-1191 REVIEW ARTICLE ISSN: 1570-159X eISSN: 1875-6190 Impact Factor: 3.365 Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids BENTHAM SCIENCE Elzbieta Rebas1, Tomasz Radzik1, Tomasz Boczek1,2 and Ludmila Zylinska1,* 1Department of Molecular Neurochemistry, Faculty of Health Sciences, Medical University of Lodz, Poland; 2Boston Children’s Hospital and Harvard Medical School, Boston, USA Abstract: Background: Neurosteroids form the unique group because of their dual mechanism of action. Classically, they bind to specific intracellular and/or nuclear receptors, and next modify genes transcription. Another mode of action is linked with the rapid effects induced at the plasma membrane level within seconds or milliseconds. The key molecules in neurotransmission are calcium ions, thereby we focus on the recent advances in understanding of complex signaling crosstalk between action of neurosteroids and calcium-engaged events.
    [Show full text]
  • Naturopathic Physicians Regulation
    PROPOSED AMENDMENTS – NATUROPATHIC PHYSICIANS REGULATION Health Professions Act NATUROPATHIC PHYSICIANS REGULATION PROPOSED TO REPLACE B.C. REG. 282/2008 Contents 1 Definitions 2 College name 3 Reserved titles 4 Scope of practice 5 Restricted activities 6 Limits or conditions on services and restricted activities 7 Patient relations program 8 Health profession corporations 1 PROPOSED AMENDMENTS – NATUROPATHIC PHYSICIANS REGULATION Definitions 1 In this regulation: "Act" means the Health Professions Act; "compound" means (a) in respect of a drug, to mix with one or more other ingredients, and (b) in respect of a therapeutic diet, to mix two or more ingredients; "dispense" has the same meaning as in the Pharmacy Operations and Drug Scheduling Act, but excludes a sale, as defined in that Act; "drug" means, except in the definition of "substance", a drug (a) specified in Schedule I of the Drug Schedules Regulation, B.C. Reg. 9/98, other than a drug set out in the Schedule of this regulation, or (b) specified in Schedule II of the Drug Schedules Regulation; "enteral instillation" means instillation directly into the gastrointestinal tract; "minor surgery" means a surgical procedure that (a) is performed, for a diagnostic or therapeutic purpose, on a superficial anatomical structure, and (b) does not involve (i) sedation, general anaesthesia or respiratory assistance, or (ii) a material risk to life; "naturopathic medicine" means the health profession in which a person provides the services of prevention, assessment and treatment of an individual's
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Central and Peripheral Neurotoxic Effects of Ivermectin in Rats
    FULL PAPER Toxicology Central and Peripheral Neurotoxic Effects of Ivermectin in Rats Saša M TRAILOVIĆ1) and Jelena Trailović NEDELJKOVIĆ2) 1)Faculty of Veterinary Medicine, Department of Pharmacology and Toxicology, University of Belgrade, Bulevar oslobodjenja 18, Belgrade 11000 and 2)Faculty of Veterinary Medicine, Department of Nutrition, University of Belgrade, Bulevar oslobodjenja 18, Belgrade 11000, Serbia (Received 27 September 2010/Accepted 6 December 2010/Published online in J-STAGE 20 December 2010) ABSTRACT. Ivermectin is considered a very safe drug; however, there are reports of toxic effects in particularly sensitive populations or due to accidental overdose. The aim of this study was (1) to further characterize the central and peripheral toxic effects of ivermectin in animals and (2) to determine possible therapeutic strategies for use in cases of ivermectin poisoning. We tested the effects of exper- imental doses of ivermectin previously reported to cause various intensities of CNS depression. However, in our study, ivermectin at 2.5, 5.0 and 7.5 mg/kg i.v. did not produce visible CNS depression in rats and 10 mg/kg resulted in sleepiness and staggering 10 to 40 min after application, while a dose of 15 mg/kg caused CNS depression very similar to general anesthesia. Ivermectin dose-dependently potentiates thiopentone-induced sleeping time in rats. Flumazenil (0.2 mg/kg), the benzodiazepine antagonist, did not affect the action of thiopentone; however, it significantly reduced sleeping time in rats treated with a combination of ivermectin (10 mg/kg) and thiopen- tone (25 mg/kg; from 189.86 45.28 min to 83.13 32.22 min; mean SD).
    [Show full text]